Bristol Myers: Opdivo Plus Yervoy Beats Chemo in Mesthelioma Patients

CheckMate -743 is the first and only Phase 3 trial in which first-line immunotherapy treatment improved survival in patients with malignant pleural mesothelioma

With these positive results, Opdivo plus Yervoy has now shown clinical benefit in six different tumor types, including durable, superior overall survival vs. chemotherapy in two thoracic cancers

https://www.marketscreener.com/BRISTOL-MYERS-SQUIBB-COMP-11877/news/Bristol-Myers-Squibb-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Demonstrates-Durable-Survival-B-31087197/